tbuckley/cabot-search huggingface dataset:
Exosomes influence the behavior of human mesenchymal stem cells on titanium surfaces
Authors: Xiaoqin Wang, Furqan A. Shah, Forugh Vazirisani, Anna Johansson, Anders Palmquist, Omar Omar, Karin Ekström, Peter Thomsen
Journal: Biomaterials (2019)

Mesenchymal stem cells (MSCs) have important roles during osseointegration. This study determined (i) if MSC-derived extracellular vesicles (EVs)/exosomes can be immobilized on titanium (Ti) surfaces and influence the behavior of MSCs, (ii) if the response is differentially affected by EVs from expanded vs differentiated MSCs and (iii) if the EV protein cargos predict the functional features of the exosomes. EVs secreted by human adipose-derived MSCs were isolated by ultracentrifugation and analyzed using nanoparticle tracking analysis, Western blotting and relative quantitative mass spectrometry. Fluorescence microscopy, scanning electron microscopy, cell counting assay and quantitative polymerase chain reaction were used to analyze MSC adhesion, proliferation and differentiation. Exosome immobilization on Ti promoted MSC adhesion and spreading after 24 h and proliferation after 3 and 6 days, irrespective of whether the exosomes were obtained from expansion or differentiation conditions. Immobilized exosomes upregulated stromal cell-derived factor (SDF-1α) gene expression. Cell adhesion molecules and signaling molecules were abundant in the exosomal proteome. The predicted functions of the equally-abundant proteins in both exosome types were in line with the observed biological effects mediated by the exosomes. Thus, exosomes derived from MSCs and immobilized on Ti surfaces interact with MSCs and rapidly promote MSC adhesion and proliferation. These findings provide a novel route for modification of titanium implant surfaces.
Concurrent hypofractionated chemoradiation (CRT) for head and neck squamous cancer with weekly cisplatin: A Lancashire experience
Authors: M. Sivaramalingam, A. Mehta, H. Wong, N. Sidek
Journal: Journal of Clinical Oncology (2009)

e17052 Background: Concurrent chemoradiation with intravenous cisplatin is the standard treatment for locally advanced head and neck cancer. We evaluated the use of hypofractionated radiotherapy and weekly concomitant cisplatin in our center. Methods: We retrospectively analysed 37 patients treated at our centre from August 2005 to November 2007. They received weekly concurrent chemoradiation with cisplatin 30 mg/m2 with radiotherapy 65Gy in 30 fractions. We analysed tumour sites, changes in weight as an indirect measure of nutritional status, calculated creatinine clearance to assess nephrotoxicity, sites of recurrence, progression free survival and overall survival. The minimum follow up was 6 months. Results: Our study population comprised of 61% of T4 disease while 25% of our patients had T3 disease. Nearly a third of our patients underwent radical neck dissection prior to concurrent chemoradiation. We found that 80% of our patients had completed the full course of concurrent chemoradiation. More than 50% of patients had oropharyngeal cancer while 25% hypopharyngeal cancer. Majority of patients lost weight during treatment. The mean weight loss was 3.56 kilograms, despite 90% having had prophylactic enteral feeding tubes. Eleven patients maintained their weight while on treatment. There were 11 recurrences: 5 were at the primary site, 4 had distant metastasis, 1 had combination of primary site and nodal drainage and 1 patient had only nodal relapse. Lung was the most common site of distant metastasis amongst the 4 patients. While a proportion of patients had a fall in creatinine clearance, the values did not drop below the accepted 50 mL/min.Two-year progression free survival was 68% and overall survival at 24 months was 68.7%. Conclusions: Weekly intravenous cisplatin when combined with radiotherapy 65Gy in 30 fractions was effective in treating head and neck cancer. The nephrotoxicity was within acceptable limits. Many patients lost weight with this treatment despite having prophylactic enteral feeding tubes. Our survival figures were encouraging and similar to other reports in the literature. No significant financial relationships to disclose.
Rapamycin-Loaded Biomimetic Nanoparticles Reverse Vascular Inflammation
Authors: Christian Boada, Assaf Zinger, Christopher Tsao, Picheng Zhao, Jonathan O. Martinez, Kelly Hartman, Tomoyuki Naoi, Roman Sukhovershin, Manuela Sushnitha, Roberto Molinaro, Barry Trachtenberg, John P. Cooke, Ennio Tasciotti
Journal: Circulation Research (2019)

Through localized delivery of rapamycin via a biomimetic drug delivery system, it is possible to reduce vascular inflammation and thus the progression of vascular disease.Use biomimetic nanoparticles to deliver rapamycin to the vessel wall to reduce inflammation in an in vivo model of atherosclerosis after a short dosing schedule.Biomimetic nanoparticles (leukosomes) were synthesized using membrane proteins purified from activated J774 macrophages. Rapamycin-loaded nanoparticles were characterized using dynamic light scattering and were found to have a diameter of 108±2.3 nm, a surface charge of -15.4±14.4 mV, and a polydispersity index of 0.11 +/ 0.2. For in vivo studies, ApoE-/- mice were fed a high-fat diet for 12 weeks. Mice were injected with either PBS, free rapamycin (5 mg/kg), or rapamycin-loaded leukosomes (Leuko-Rapa; 5 mg/kg) once daily for 7 days. In mice treated with Leuko-Rapa, flow cytometry of disaggregated aortic tissue revealed fewer proliferating macrophages in the aorta (15.6±9.79 %) compared with untreated mice (30.2±13.34 %) and rapamycin alone (26.8±9.87 %). Decreased macrophage proliferation correlated with decreased levels of MCP (monocyte chemoattractant protein)-1 and IL (interleukin)-b1 in mice treated with Leuko-Rapa. Furthermore, Leuko-Rapa-treated mice also displayed significantly decreased MMP (matrix metalloproteinases) activity in the aorta (mean difference 2554±363.9, P=9.95122×10-6). No significant changes in metabolic or inflammation markers observed in liver metabolic assays. Histological analysis showed improvements in lung morphology, with no alterations in heart, spleen, lung, or liver in Leuko-Rapa-treated mice.We showed that our biomimetic nanoparticles showed a decrease in proliferating macrophage population that was accompanied by the reduction of key proinflammatory cytokines and changes in plaque morphology. This proof-of-concept showed that our platform was capable of suppressing macrophage proliferation within the aorta after a short dosing schedule (7 days) and with a favorable toxicity profile. This treatment could be a promising intervention for the acute stabilization of late-stage plaques.
Deep Learning Based on Standard H&amp;E Images of Primary Melanoma Tumors Identifies Patients at Risk for Visceral Recurrence and Death
Authors: Prathamesh M. Kulkarni, Eric J. Robinson, Jaya Sarin Pradhan, Robyn D. Gartrell-Corrado, Bethany R. Rohr, Megan H. Trager, Larisa J. Geskin, Harriet M. Kluger, Pok Fai Wong, Balazs Acs, Emanuelle M. Rizk, Chen Yang, Manas Mondal, Michael R. Moore, Iman Osman, Robert Phelps, Basil A. Horst, Zhe S. Chen, Tammie Ferringer, David L. Rimm, Jing Wang, Yvonne M. Saenger
Journal: Clinical Cancer Research (2019)

Abstract Purpose: Biomarkers for disease-specific survival (DSS) in early-stage melanoma are needed to select patients for adjuvant immunotherapy and accelerate clinical trial design. We present a pathology-based computational method using a deep neural network architecture for DSS prediction. Experimental Design: The model was trained on 108 patients from four institutions and tested on 104 patients from Yale School of Medicine (YSM, New Haven, CT). A receiver operating characteristic (ROC) curve was generated on the basis of vote aggregation of individual image sequences, an optimized cutoff was selected, and the computational model was tested on a third independent population of 51 patients from Geisinger Health Systems (GHS). Results: Area under the curve (AUC) in the YSM patients was 0.905 (P &amp;lt; 0.0001). AUC in the GHS patients was 0.880 (P &amp;lt; 0.0001). Using the cutoff selected in the YSM cohort, the computational model predicted DSS in the GHS cohort based on Kaplan–Meier (KM) analysis (P &amp;lt; 0.0001). Conclusions: The novel method presented is applicable to digital images, obviating the need for sample shipment and manipulation and representing a practical advance over current genetic and IHC-based methods.
Abstract 17064: Decreased Mortality and Early Complications in AMI Patients is Homogeneous across Age Groups. A 15-year Perspective from the USIK 1995, USIC 2000, FAST-MI 2005 and 2010 French Nationwide Registries
Authors: Etienne Puymirat, Nadia Aissaoui, Jean-Louis Bonnet, Bruno Huret, Luc Maillard, Geneviève Mulak, Jean Ferrières, Jean-Pierre Cambou, Tabassome Simon, Nicolas Danchin
Journal: Circulation (2012)

Background and aim: Early mortality of AMI patients has decreased substantially over the past 2 decades. Whether this decrease more specifically affects one age class is unknown. Methods: USIK 1995...
P2.04-75 Overall Survival by IDO1 and PD-L1 Expression in NSCLC Patients Receiving an Immune Checkpoint Inhibitor (ICI)
Authors: M. Moore, R. Hall, E. Mcloughlin, J. Melson, B. Horton, A. Mills, R. Gentzler
Journal: Journal of Thoracic Oncology (2019)
EP1.01-102 Efficacy and Toxicity of Erlotinib and Gefitinib in Moroccan Patients with Advanced Non-Small Cell Lung Cancer with EGFR Mutation
Authors: N. Benchakroun, N. Minoungou, Z. Bouchbika, H. Jouhadi, N. Tawfik, S. Sahraoui, A. Benider, A. Acharki, M. Lemzah
Journal: Journal of Thoracic Oncology (2019)
P1.14-04 Final Results of the Prospective Genomics of Young Lung Cancer (GYLC), an Addario Lung Cancer Medical Institute Study
Authors: B. Gitlitz, S.L. Park, M. Bittoni, B. Addario, A. Sable-Hunt, A. Moore, D. Pavlick, S. Novello, T. Vavalà, R. Chen, G. Oxnard
Journal: Journal of Thoracic Oncology (2019)
Role of HLA-B exon 1 in graft-versus-host disease after unrelated haemopoietic cell transplantation: a retrospective cohort study
Authors: Effie W Petersdorf, Mary Carrington, Colm O'hUigin, Mats Bengtsson, Dianne De Santis, Valerie Dubois, Ted Gooley, Mary Horowitz, Katharine Hsu, J Alejandro Madrigal, Martin J Maiers, Mari Malkki, Caroline McKallor, Yasuo Morishima, Machteld Oudshoorn, Stephen R Spellman, Jean Villard, Phil Stevenson, Effie W Petersdorf, Mary Carrington, Colm O'hUigin, Mats Bengtsson, Dianne De Santis, Valerie Dubois, Ted Gooley, Mary Horowitz, Katharine Hsu, J Alejandro Madrigal, Martin Maiers, Mari Malkki, Caroline McKallor, Yasuo Morishima, Machteld Oudshoorn, Stephen Spellman, Jean Villard, Phil Stevenson, Jane Apperley, Peter Bardy, Ghislaine Bernard, Yves Bertrand, Adrian Bloor, Chiara Bonini, Stephane Buhler, Laura Bungener, Helen Campbell, Kristina Carlson, Ben Carpenter, Anne Cesbron, Christian Chabannon, Yves Chalandon, Jeremy Chapman, Réda Chebel, Patrice Chevallier, Gerda Choi, Matt Collin, Jan J Cornelissen, Charles Crawley, Lloyd D'Orsogna, Jean-Hugues Dalle, Eric Deconinck, Muriel DeMatteis, Mary Diviney, Anne Dormoy, Katia Gagne, Brenda Gibson, Maria Gilleece, David Gottlieb, John Gribben, Tayfun Güngör, Mike Haagenson, Cathie Hart, Rhonda Holdsworth, Ian Humphreys, Yoshihisa Kodera, Mickey Koh, Hélène Labussière-Wallet, Arjan C Lankester, Neubery Lardy, Sarah Lawson, Xavier Leleu, Stephen MacKinnon, Ram Malladi, Steven GE Marsh, Murray Martin, Neema P Mayor, I Grant McQuaker, Ellen Meijer, Satoko Morishima, Emmanouil Nikolousis, Kim Orchard, Jacob Passweg, Amit Patel, Katherine Patrick, Béatrice Pedron, Andy Peniket, Julia Perry, Eefke Petersen, Victoria Potter, Mike Potter, Rachel Protheroe, Nicole Raus, Carmen Ruiz de Elvira, Nigel Russell, Nicholaas PM Schaap, Urs Schanz, Harry Schouten, Roderick Skinner, John Snowden, Eric Spierings, Colin Steward, Eleni Tholouli, Alycia Thornton, Marcel Tilanus, Arnold van de Meer, Hendrik Veelkens, Paul Veys, Narelle Watson, Lyanne Weston, Keith Wilson, Marie Wilson, Robert Wynn, József Zsiros
Journal: The Lancet Haematology (2019)
FEV<sub>1</sub>:FVC Thresholds for Defining Chronic Obstructive Pulmonary Disease—Reply
Authors: Surya P. Bhatt, Joseph E. Schwartz, Elizabeth C. Oelsner
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
MA04.09 Study of Exosomes in NSCLC for Biomarkers Searching
Authors: E. Durendez-Saez, S. Calabuig-Fariñas, C. Suarez, M. Mosqueda, S. Gallach, E. Escorihuela, A. Moreno, S. Torres, A. Herreros-Pomares, Á. González, E. De La Cueva, E. Serna, J. Paramio, E. Jantus-Lewintre, C. Camps
Journal: Journal of Thoracic Oncology (2019)
EP1.11-19 Surveillance with PET/CT and ctDNA of Lung Cancer Patients After Completion of Definitive Therapy; A Randomized Trial
Authors: K. Skougaard, K. Guldbrandsen, O. Østrup, U. Bødtger, M. Frank, T. Schytte, B. Sorensen, T. Rasmussen, O. Gerke, J. Søgaard, B. Rychwicka-Kielek, Z. Saghir, G. Persson, B. Fischer
Journal: Journal of Thoracic Oncology (2019)
Prevalence and Characteristics of Avoidant/Restrictive Food Intake Disorder in Adult Neurogastroenterology Patients
Authors: Helen Burton Murray, Abbey P. Bailey, Ani C. Keshishian, Casey J. Silvernale, Kyle Staller, Kamryn T. Eddy, Jennifer J. Thomas, Braden Kuo
Journal: Clinical Gastroenterology and Hepatology (2019)
Quality of surgical resection for non-small cell lung cancer (NSCLC) in a U.S. metropolitan area
Authors: J. W. Allen, R. Osarogiagbon, A. Farooq, M. Ninan, T. F. O'Brien
Journal: Journal of Clinical Oncology (2009)

7512 Background: Curative treatment of early stage NSCLC requires good quality oncologic resection (GQR). For GQR, the National Comprehensive Cancer Network (NCCN) requires a minimum of segmentectomy, negative margins, lymph node (LN) sampling from stations 10–14 (level-1) and &gt;2 mediastinal (level-2) stations. We reviewed details of consecutive resections for NSCLC to determine the proportion that met NCCN GQR criteria and the proportion who would have met eligibility for the RADIANT trial which requires &gt;1 level-2 stations. Methods: Retrospective review of medical records of all patients who underwent curative- intent resection for NSCLC in the Memphis Metropolitan Area from 1/1/2004 to 12/31/2007. Resections for benign and metastatic disease were excluded. Death information was obtained from a national death index search. Categorical variables were compared by chi-square test or Fisher's exact test, survival curves by log-rank test. Results: 746 patients were eligible (Table). Median age was 67.7 (range, 36.5 - 89.4). 61/746 (8.2%) met NCCN GQR criteria. Black patients were more likely than whites to have GQR (P=0.022). No other patient demographic factor was associated with GQR. Three year survival was 72% in those with GQR versus 63% in those without GQR (P=0.50). There was a difference in achievement of GQR between the 3 major institutions where surgery was done (P=0.001) although it was low across the board. 77.9% of patients would have been disqualified from the RADIANT trial. Conclusions: Majority of surgical resections for NSCLC did not achieve GQR standards per RADIANT and NCCN. The greatest deficit is in surgical sampling of level-2 LNs, but evaluation of level-1 LNs is also frequently sub-optimal. Intervention is needed to improve current surgical and pathology practices in collection and examination of surgical specimens in order to achieve minimum standards for accurate staging, prognostication, determination of candidacy for post-operative adjuvant therapy, and eligibility for clinical trials. [Table: see text] [Table: see text]
P2.01-102 Outcome of Patients with EGFR Exon 19 Mutation in a Phase III Randomized Trial Comparing Gefitinib to Gefitinib with Chemotherapy
Authors: K. Prabhash, V. Noronha, V. Patil, A. Joshi, A. Chougule, A. Mahajan, A. Janu, R. Kumar, S. More, S. Goud, N. Kumar, N. Daware, A. Bhattacherjee, S. Shah, A. Yadav, S. Banavali
Journal: Journal of Thoracic Oncology (2019)
OA06.06 Independent Validation of a Novel High-Resolution Computed Tomography-Based Radiomic Classifier for Indeterminate Lung Nodules
Authors: T. Peikert, F. Duan, S. Rajagopalan, R. Karwoski, A. Balar, D. Lakhani, S. Antic, B. Bartholmai, J. Tucker, P. Massion, F. Maldonado
Journal: Journal of Thoracic Oncology (2019)
JCSE01.28 Changes of Brain Structure in Advanced NSCLC Patients Receiving EGFR-TKIs: Dynamic Analysis Based on Series MRI Images
Authors: C. Luo, B. Yang, X. Zhou, L. Zhou, Y. Zhou, J. Zhu, M. Huang, F. Peng, Y. Liu, Y. Wang, Z. Li, Y. Lu, S. Lui, Y. Gong
Journal: Journal of Thoracic Oncology (2019)
IgG Fc glycosylation as an axis of humoral immunity in childhood
Authors: Hao D. Cheng, Irit Tirosh, Noortje de Haan, Henning Stöckmann, Barbara Adamczyk, Ciara A. McManus, Róisín O’Flaherty, Gordon Greville, Radka Saldova, Francisco A. Bonilla, Luigi D. Notarangelo, Gertjan J. Driessen, Ingrid A. Holm, Pauline M. Rudd, Manfred Wuhrer, Margaret E. Ackerman, Peter A. Nigrovic
Journal: Journal of Allergy and Clinical Immunology (2019)
P1.01-117 Pulmonary Function Monitoring in Patients with Oligometastatic NSCLC Who Receive Stereotactic Body Radiation Therapy
Authors: M. Arroyo-Hernandez, M. Blake-Cerda, L. Gochicoa-Rangel, S. Monraz-Pérez, M.F. Cuevas Góngora, D. Valle Bautista, P.A. Barragán Castillo, F. Maldonado Magos, O. Rodríguez, D. Flores, O.G. Arrieta
Journal: Journal of Thoracic Oncology (2019)
P1.06-17 Tumor Treating Fields (150 kHz) Combined with Cisplatin or Pemetrexed Inhibits Mesothelioma Cells in Vitro and in Vivo
Authors: M. Munster, K. Gotlib, R. Schneiderman, Y. Porat, T. Voloshin, S. Davidi, A. Shteingauz, N. Kaynan, E. Zeevi, M. Giladi, E. Kirson, U. Weinberg, A. Kinzel, Y. Palti
Journal: Journal of Thoracic Oncology (2019)
Milker’s Nodule
Authors: Puravoor Jayasree, Feroze Kaliyadan, Ranjima Abraham
Journal: JAMA Dermatology (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
EP1.09-11 Lipoid Pneumonia Resembling Bilateral Lung Cancer: Be Aware of Nasal Decongestants!
Authors: C. Braggio, G. Bocchialini, L. Ventura, P. Carbognani, M. Tiseo, L. Gnetti, M. Rusca, L. Ampollini
Journal: Journal of Thoracic Oncology (2019)
P1.01-69 Blood Serum Amyloid A as Potential Predictor of Response to First-Line Pembrolizumab in Patients with Advanced Non-Small-Cell Lung Cancer
Authors: V. Di Noia, C. Carbone, E. Vita, M. Ferrara, E. D'Argento, D. Lucchetti, P. Damiano, A. Virtuoso, M. Ribelli, A. Cannella, A. Battaglia, A. Fattorossi, A. Sgambato, G. Tortora, E. Bria
Journal: Journal of Thoracic Oncology (2019)
A Bayesian Framework for Inferring the Influence of Sequence Context on Point Mutations
Authors: Guy Ling, Danielle Miller, Rasmus Nielsen, Adi Stern
Journal: Molecular Biology and Evolution (2019)

The probability of point mutations is expected to be highly influenced by the flanking nucleotides that surround them, known as the sequence context. This phenomenon may be mainly attributed to the enzyme that modifies or mutates the genetic material, because most enzymes tend to have specific sequence contexts that dictate their activity. Here, we develop a statistical model that allows for the detection and evaluation of the effects of different sequence contexts on mutation rates from deep population sequencing data. This task is computationally challenging, as the complexity of the model increases exponentially as the context size increases. We established our novel Bayesian method based on sparse model selection methods, with the leading assumption that the number of actual sequence contexts that directly influence mutation rates is minuscule compared with the number of possible sequence contexts. We show that our method is highly accurate on simulated data using pentanucleotide contexts, even when accounting for noisy data. We next analyze empirical population sequencing data from polioviruses and HIV-1 and detect a significant enrichment in sequence contexts associated with deamination by the cellular deaminases ADAR 1/2 and APOBEC3G, respectively. In the current era, where next-generation sequencing data are highly abundant, our approach can be used on any population sequencing data to reveal context-dependent base alterations and may assist in the discovery of novel mutable sites or editing sites.
P1.01-129 Preclinical Genetic Evaluation of Alternating ALK TKI Therapy Versus Continuous Dosing in ALK NSCLC to Inform the ALKternate Clinical Trial
Authors: M. Itchins, A. Hudson, S. Hayes, R. Harvie, G.H. Wei, M. Buckland, S. Clarke, V. Howell, N. Pavlakis
Journal: Journal of Thoracic Oncology (2019)
EP1.04-17 The Association of Clinicopathologic Features and Peripheral Blood Parameters with High PD-L1 Expression in Non-Small Cell Lung Cancer
Authors: B. Bilgin, M. Hizal, S. Yucel, M.A. Sendur, N. Akyurek, M.B. Akinci, U. Yilmaz, B. Yalcin
Journal: Journal of Thoracic Oncology (2019)